Furthermore, the combination of SCR‐7952 with SAM‐competitive or MTA‐cooperative PRMT5 inhibitors supported further investigation and potential development of an effective strategy for larger therapeutic windows on MTAP‐deleted cancers. Here, PRMT5 is linked to cancer.